Lipid panel testing market seen reaching $17.79 billion by 2030

The global lipid panel testing market is projected to grow from $11.61 billion in 2025 to $17.79 billion by 2030 as cardiovascular and metabolic disease rates rise and preventive screening expands. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Lipid panel testing is becoming a bigger part of preventive care as heart disease, diabetes and cholesterol management needs rise worldwide. - The market’s growth points to stronger demand for routine screening, at-home testing and faster diagnostic tools. - The report projects the market will reach $17.79 billion by 2030, underscoring a sustained shift toward early risk detection.

What happened: - The Business Research Company released a lipid panel testing market outlook on Aug. 14, 2026. - The report says the market will grow from $11.61 billion in 2025 to $12.61 billion in 2026. - The forecast calls for a 9.0% compound annual growth rate from 2026 to 2030. - The report covers market size, trends and global forecasts for 2026-2035. - A free sample is available here.

The details: - Lipid panel testing measures fats in the blood, including cholesterol and triglycerides. - The test is used to assess cardiovascular risk, diagnose lipid disorders, guide treatment and monitor patient progress. - Growth in the historical period was linked to higher cardiovascular disease prevalence, wider routine screenings, greater awareness of cholesterol management, broader use of automated diagnostic technologies and better access to testing. - Future growth is expected to be supported by preventive healthcare, at-home diagnostic demand, digital health platform integration, AI-powered diagnostic tools and population-wide screening programs. - Emerging trends include more point-of-care lipid testing, increased use of automated analyzers, stronger interest in early cardiovascular risk screening, growth in home-based test kits and faster risk assessment. - The report says cardiovascular disease and diabetes increase lipid imbalances and make lipid testing important for early diagnosis and long-term management. - The American College of Cardiology reported global cardiovascular deaths reached 19.2 million in 2023. - The full report is available here.

Between the lines: - The forecast reflects a broader healthcare shift from treatment toward prevention and earlier intervention. - The emphasis on home-based kits, AI tools and point-of-care testing suggests buyers want faster results and easier access outside traditional labs. - North America’s lead indicates mature diagnostic infrastructure, while Asia-Pacific’s expected pace suggests room for healthcare investment and screening expansion. - The report also includes South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa, signaling a broad global market opportunity.

What's next: - The market is expected to keep expanding through 2030 as chronic disease screening becomes more routine. - Adoption should increase for automated analyzers, home testing and digital diagnostic workflows. - The report highlights updated market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and refreshed trend analysis in its 2026 edition. - The Business Research Company invited interested readers to contact its expert team for more information.

The bottom line: - Lipid panel testing is moving from a standard lab test to a fast-growing preventive diagnostics market with global demand and strong long-term growth potential.